Mitoquinone Mesylate

DRUG3 trials

Sponsors

Antipodean Pharmaceuticals, Inc., Ball State University, UConn Health

Conditions

AgingArterial StiffnessCardiovascular FunctionEndothelial DysfunctionFrailtyMild Cognitive ImpairmentNon-alcoholic Fatty Liver Disease

Phase 2

A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD)

TerminatedNCT01167088

Antipodean Pharmaceuticals, Inc.Non-alcoholic Fatty Liver Disease

Start: 2010-11-30End: 2011-07-31Target: 110Updated: 2011-06-01

The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults

RecruitingNCT06027554

UConn HealthAging, Frailty, Mild Cognitive Impairment

Start: 2024-10-07End: 2028-02-01Target: 60Updated: 2026-08-12

Unknown Phase

Role of Mitochondrial-derived Oxidative Stress to Promote Vascular Endothelial Dysfunction in Non-exercisers With Aging

CompletedNCT05872139

Ball State UniversityAging, Arterial Stiffness, Cardiovascular Function +1

Start: 2022-09-23End: 2023-05-01Updated: 2023-05-24